Efficacy and safety of TNF-α inhibitors in refractory primary complex aphthosis: a patient series and overview of the literature

References

• Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J. 1975;113:627–630.
   PubMed Web of Science ®Google Scholar
• Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: A large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol. 2005;52:500–508.
   Google Scholar
• Jorizzo JL, Taylor RS, Schmalstieg FC, Solomon AR, Daniels JC, Rudloff HE, et al. Complex aphthosis: A forme fruste of Behcet's syndrome ? J Am Acad Dermatol. 1985;13:80–84.
   Google Scholar
• Keogan MT. Clinical Immunology Review Series: An approach to the patient with recurrent orogenital ulceration, including Behcet's syndrome. Clin Exp Immunol. 2009;156:1–11.
   PubMed Web of Science ®Google Scholar
• Brocklehurst P, Tickle M, Glenny AM, Lewis MA, Pemberton MN, Taylor J, et al. Systemic interventions for recurrent aphthous stomatitis (mouth ulcers). Cochrane Database Syst Rev. 2012;9:CD005411.
   Google Scholar
• Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;15:443–450.
   Google Scholar
• Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a double blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267–279.
   PubMed Web of Science ®Google Scholar
• Katz J, Langevitz P, Shemer J, Barak S, Livneh A. Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Am Acad Dermatol. 1994;31:459–461.
   PubMed Web of Science ®Google Scholar
• Lynde CB, Bruce AJ, Rogers RS. Successful treatment of complex aphthosis with colchicine and dapsone. J Acad Dermatol. 2009;145:273–276.
   Google Scholar
• Robinson ND, Guitart J. Recalcitrant recurrent aphthous stomatitis treated with etanercept. Arch Dermatol. 2003;139:1259–1262.
   PubMed Web of Science ®Google Scholar
• Vujevich J, Zirwas M. Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis. 2005;76:129–132.
   Google Scholar
• Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ortego-Centeno N. Recalcitrant, recurrent aphthous stomatitis successfully treated with adalimumab. J Eur Acad Dermatol Venereol. 2009;23:206.
   Google Scholar
• O'Neill ID. Efficacy of tumour necrosis factor-alpha antagonists in aphthous ulceration: review of published individual patient data. J Eur Acad Dermatol Venereol. 2011;26:231–235.
   Google Scholar
• Estrach C, Mpofu S, Moots RJ. Behcet's syndrome: response to infliximab after failure with etanercept. Rheumatology. 2002;41:1213–1214.
   Google Scholar
• Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology. 2001;40:473–474.
   PubMed Web of Science ®Google Scholar
• Aikawa NE, Gonçalves C, Silva CA, Gonçalves C, Bonfá E, de Carvalho JF. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease. Rheumatol Int. 2011;31:1097–1099.
   Google Scholar
• Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001;60:637.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Debus D, Schuler G, Hertl M. Infliximab in a patient with refractory mucosal aphthosis. J Eur Acad Dermatol Venereol. 2008;22:109–110.
   PubMed Web of Science ®Google Scholar
• Scheinberg MA. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol. 2002;20:733–734.
   Google Scholar
• Kaufman I, Caspi D, Yeshurrun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005;25:406–410.
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98–105.
   PubMed Web of Science ®Google Scholar
• Connally M, Armstrong JS, Buckley DA. Infliximab treatment for severe orogenital ulceration in Behcet's disease. Br J Dermatol. 2005;153:1073–1075.
   Google Scholar
• Almoznino G, Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Behcet's disease: a case report and review of the literature. Clin Exp Rheumatol. 2007;25:S99–S102.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M. Successful treatment of Behcet's disease with etanercept. Clin Exp Rheumatol. 2005;23:729.
   Google Scholar
• Curigliano V, Giovinale M, Fonnesu C, Cerquaglia C, Verrecchia E, Turco S, et al. Efficacy of etanercept in the treatment of a patient with Behcet's disease. Clin Rheumatol. 2008;27:933–936.
   PubMed Web of Science ®Google Scholar
• Perra D, Alba MA, Callejas JL, Mesquida M, Rios-Fernande Z, Adan A, et al. Adalimumab for the treatment of Behcet's disease: experince in 19 patients. Rheumatology. 2012;51:1825–1831.
   PubMed Web of Science ®Google Scholar
• Sanchez AR, Rogers RS 3rd, Sheridan PJ. Oral ulcerations are associated with the loss of response to infliximab in Crohn's disease. J Oral Pathol Med. 2005;34:53–55.
   PubMed Web of Science ®Google Scholar
• Sfikasis PP. Behcet's disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis. 2002;61:51–53.
   Google Scholar
• Turan B, Gallati H, Erdi H, Gurler BA, Michel BA, Villinger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-2 in Behcet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128–132.
   PubMed Web of Science ®Google Scholar